Recruiting Clinical Trials

Trial Of Pembrolizumab And Nintedanib

By April 24, 2017No Comments

Condition

Patients With Any Advanced Solid Tumors.

Estimated Enrollment: 18

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 2015-004511-21|2015/2329

Study First Received: August 2, 2016

Last Updated: August 4, 2016

Estimated Primary Completion Date: July 2021

 

Primary Outcome Measures:

MTD of Nintedanib

Sponsors and Collaborators:

Gustave Roussy, Cancer Campus, Grand Paris

Website Link: https://ClinicalTrials.gov/show/NCT02856425

Leave a Reply

Call Now ButtonCall Now